Latest revenue
$45.1M
as of 2026-03-31
Latest net income
$-10.5M
as of 2026-03-31
Net margin
-23.3%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think AMRN is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $5.3M
- Enterprise value
- $-116.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.01×
- Dividend yield
- 0.0%
- 52-wk high
- $20.90
- 52-wk low
- $11.65
- Beta
- —
- Shares out
- 380.7K
5-year trend
What this company does
Item 1. Business References in this Annual Report on Form 10-K to “Amarin,” the “Company,” “we,” “our” and “us” refer to Amarin Corporation plc and its subsidiaries, on a consolidated basis, unless otherwise indicated. This Annual Report on Form 10-K, or Annual Report, includes the registered and unregistered trademarks and service marks of other parties. Amarin Corporation plc is a public limited company incorporated under the laws of England and Wales. Amarin Corporation plc was originally incorporated in England as a private limited company on March 1, 1989 under the Companies Act 1985, and re-registered in England as a public limited company on March 19, 1993. Our principal office is…
AI summary unavailable — showing raw filing excerpt
Generated from AMRN's filing dated 2026-03-02
Key risks
Item 1A. Risk Factors This Annual Report on Form 10-K contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements that we make or that are made on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our ability to successfully commercialize VASCEPA and VAZKEPA, collectively referred to as VASCEPA, our capital resources, the progress and timing of our clinical programs, the safety and efficacy of our product candidates, risks associated with regulatory filings, the potential clinical benefits and market…
AI summary unavailable — showing raw filing excerpt
Generated from AMRN's filing dated 2026-03-02
Profitability
Gross margin
56.6%
58.9%Operating margin
-23.5%
41.5%Net margin
-18.2%
49.5%Return on equity
-8.4%
50.0%Return on assets
-5.8%
51.8%Leverage
Debt / equity
0.46×
12.4%Debt / assets
31.5%
8.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $45.1M | +7.4% | $-10.5M | +33.0% | -23.3% |
Q4 2025 2025-12-31 | $49.2M | -21.0% | $-1.2M | +97.5% | -2.5% |
Q3 2025 2025-09-30 | $49.7M | +17.4% | $-7.7M | +69.2% | -15.6% |
Q2 2025 2025-06-30 | $72.7M | +7.8% | $-14.1M | -1029.0% | -19.4% |
Q1 2025 2025-03-31 | $42.0M | -25.7% | $-15.7M | -57.7% | -37.4% |
Q4 2024 2024-12-31 | $62.3M | — | $-48.6M | — | -78.0% |
Q3 2024 2024-09-30 | $42.3M | -36.0% | $-25.1M | -30.2% | -59.4% |
Q2 2024 2024-06-30 | $67.5M | -15.8% | $1.5M | +108.7% | 2.3% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AMRN — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AMRN
Institutional value
$6.3M
Total shares held
1.1M
Distinct holders
34
-47 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | Waterfront Wealth Inc. | 203.3K | $2.9M | +60.8K (+42.7%) | Added |
| 2 | BNP PARIBAS FINANCIAL MARKETS | 75.5K | $1.1M | -28.8K (-27.6%) | Trimmed |
| 3 | LCM Capital Management Inc | 43.5K | $628.5K | +1.2K (+2.8%) | Added |
| 4 | Bleakley Financial Group, LLC | 23.6K | $340.7K | +75 (+0.3%) | Added |
| 5 | State of New Jersey Common Pension Fund D | 18.9K | $273.0K | +0 (+0.0%) | No change |
| 6 | COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS | 18.4K | $265.6K | +0 (+0.0%) | No change |
| 7 | UBS Group AG | 13.2K | $190.8K | +9.0K (+211.4%) | Added |
| 8 | WELLS FARGO & COMPANY/MN | 11.4K | $164.6K | +2.1K (+23.0%) | Added |
| 9 | Steward Partners Investment Advisory, LLC | 9.0K | $129.6K | +68 (+0.8%) | Added |
| 10 | NEW YORK STATE COMMON RETIREMENT FUND | 7.6K | $110.0K | +0 (+0.0%) | No change |
| 11 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 5.8K | $83.1K | -1.6K (-21.5%) | Trimmed |
| 12 | RHUMBLINE ADVISERS | 3.3K | $48.3K | +299 (+9.8%) | Added |
| 13 | BlackRock, Inc. | 1.2K | $16.8K | -2.3K (-66.3%) | Trimmed |
| 14 | Farther Finance Advisors, LLC | 962 | $14.1K | +20 (+2.1%) | Added |
| 15 | IFP Advisors, Inc | 814 | $11.8K | +700 (+614.0%) | Added |
| 16 | ACADIAN ASSET MANAGEMENT LLC | 636.8K | $9.2K | +56.3K (+9.7%) | Added |
| 17 | CoreCap Advisors, LLC | 535 | $7.7K | +0 (+0.0%) | No change |
| 18 | GAMMA Investing LLC | 530 | $7.7K | +264 (+99.2%) | Added |
| 19 | JPMORGAN CHASE & CO | 242 | $3.4K | -18.5K (-98.7%) | Trimmed |
| 20 | TWIN PEAKS WEALTH ADVISORS, LLC | 224 | $3.2K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AMRN's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.